This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001

This study has been completed.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: December 15, 2011
Last updated: November 6, 2014
Last verified: December 2013
The purpose of this study is to provide subjects who participated in prior studies of EXC 001 the opportunity to have their hypertrophic scars surgically revised and treated with EXC 001.

Condition Intervention Phase
Reduction in Severity of Skin Scarring Drug: EXC 001 (currently called PF-06473871) Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Open-label Study to Provide Revision of Scars Resulting From Surgery in Prior Studies of EXC 001 (Currently Called PF-06473871)

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Assess the safety of EXC 001 in subjects undergoing elective revision of scars from prior surgery [ Time Frame: Week 24 ]

Secondary Outcome Measures:
  • Physician Scar Assessment Scale [ Time Frame: Wk 24 ]
  • Subject Scar Assessment Scale [ Time Frame: Wk 24 ]
  • Physician Reported Scar Severity Scale (Photonumeric Guide) [ Time Frame: Wk 24 ]
  • Subject Reported Scar Severity Scale (Photonumeric Guide) [ Time Frame: Wk 24 ]

Enrollment: 14
Study Start Date: December 2011
Study Completion Date: September 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Open Label Drug: EXC 001 (currently called PF-06473871)
Single dose administered by injection at four different times


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Healthy adults who have participated in previous studies of EXC 001.
  • Healthy adults who have chosen to have their scars revised.

Exclusion Criteria:

  • Currently pregnant or pregnant during the 6 months prior to inclusion in the study, or breast feeding.
  • Participation in another clinical trial within 30 days prior to the start of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01494922

United States, Florida
Pfizer Investigational Site
Lake Worth, Florida, United States, 33461
United States, Illinois
Pfizer Investigational Site
Chicago, Illinois, United States, 60611
United States, Oregon
Pfizer Investigational Site
Eugene, Oregon, United States, 97401
Pfizer Investigational Site
Tualatin, Oregon, United States, 97062
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Pfizer Identifier: NCT01494922     History of Changes
Other Study ID Numbers: EXC 001-206
Study First Received: December 15, 2011
Last Updated: November 6, 2014

Keywords provided by Pfizer:
Skin scarring
hypertrophic scar
hypertrophic scar prevention

Additional relevant MeSH terms:
Pathologic Processes processed this record on September 21, 2017